PubMed · 2023

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet.

Lancet

Source: https://pubmed.ncbi.nlm.nih.gov/37385280/

Last reviewed August 12, 2026. By the PeptIQ team.

View original source

Peptides linked in PeptIQ Wiki

Retatrutide — community report

This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.